Comparative Evaluation of the Efficacy of Treatment with Intravenous Lignocaine and Intravenous Granisetron in Prevention of Pain Due to Intravenous Injection of Propofol

Anas Khaled Abdel Moniem Mohamed;

Abstract


Propofol is today considered the most common intravenous drug for the induction of general anesthesia. It is a drug with Phenol structure whose common complication is pain at the injection site as well as low blood pressure.
This study was carried-out for Comparison of treatment with granisetron versus lignocaine with respect to improvement of pain induced by injection of propofol, in patient admitted for elective surgery under general anesthesia.
This study was carried-out on 284 patients belonging to American Society of Anesthesiologists (ASA) physical status (PS) 1 and 2, of either sex, aged 18–60 years, scheduled for various elective surgical procedures under general anesthesia.
The patients divided into 2 groups; Group 1 that consist of 142 patients which received injection of intravenous propofol (1-2 mg/kg) after injection with 1 ml of 2% lignocaine. Group 2 consist of another 142 which received injection of intravenous propofol (1-2 mg/kg) after injection with 1 ml of 1ml of granisetron (1 mg/ml).
Our results concluded that:
1. The demographic data (age, body weight, sex ratio), physical status and type of surgery are not differ significantly (P > 0.05) among the two groups of this study.


Other data

Title Comparative Evaluation of the Efficacy of Treatment with Intravenous Lignocaine and Intravenous Granisetron in Prevention of Pain Due to Intravenous Injection of Propofol
Other Titles تقييم مقارن لفعالية المعالجة بالليجنوكين في الوريد أوالجرانيسيترون في الوريد للوقاية من الألم بسبب الحقن الوريدي للبروبوفول
Authors Anas Khaled Abdel Moniem Mohamed
Issue Date 2021

Attached Files

File SizeFormat
BB7904.pdf880.91 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check



Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.